Kezar Life Sciences
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $-5,428 |
Gross Profit | -261 | -260 | -5,708 | |
EBITDA | -21,948 | -20,885 | -20,998 | -31,581 |
EBIT | -22,208 | -21,146 | -21,258 | -31,861 |
Net Income | -20,313 | -21,547 | -21,658 | -32,259 |
Net Change In Cash | 0 | 0 | 0 | -5,428 |
Free Cash Flow | -17,512 | -17,031 | -22,862 | -18,981 |
Cash | 34,858 | 28,276 | 33,031 | 35,493 |
Basic Shares | 72,962 | 7,284 | 72,799 | 72,736 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $7,000 | $0 | $0 | $0 |
Gross Profit | -70,085 | -1,022 | -1,510 | -1,544 |
EBITDA | -99,254 | -70,139 | -52,961 | -41,406 |
EBIT | -100,320 | -71,162 | -54,471 | -42,950 |
Net Income | -101,870 | -65,316 | -53,279 | -38,990 |
Net Change In Cash | 7,000 | 0 | 0 | 0 |
Cost of Revenue | -22,377 | 41,704 | 6,195 | |
Free Cash Flow | -83,455 | -60,424 | -42,753 | -37,143 |
Cash | 35,493 | 40,456 | 62,882 | 21,228 |
Basic Shares | 72,553 | 67,368 | 52,759 | 44,004 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$2.78 |
2024-06-30 | -$0.27 |
2024-03-31 | -$0.30 |
2023-12-31 | -$0.44 |
